All News
Filter News
Found 217 articles
-
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
9/27/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021.
-
This marks the second vaccine against the novel coronavirus developed by the India-based company and brings a significant milestone for intranasal formulations.
-
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
9/7/2021
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.
-
By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone.
-
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
8/10/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and six-months ending June 30, 2021 and provided a corporate update.
-
Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021
8/4/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021.
-
Meissa’s intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting.
-
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look. -
The company said it would halt activities and focus its resources and time on liver and obesity research following "disappointing" results of its intranasal COVID-19 vaccine.
-
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
6/29/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19.
-
Biodefense Market Size to Reach USD 8.32 Billion by 2028 – Report and Data
6/29/2021
Government funding for preparedness of bioterrorist attacks is a key factor that would drive global market growth.
-
Biodefense Market Outstrip US$ 8,350.74 Mn in 2027 and to grow with a CAGR of 9.4% says, The Insight Partners
6/23/2021
The market is estimated to grow with a CAGR of 9.4% from 2020-2027.
-
Clinical Catch-Up: June 14-18
6/21/2021
It was another busy week of clinical trial announcements. Here’s a look. -
The company’s lead candidate, INNA-051, is an innate immune agonist that directly stimulates the host’s natural immune defense system.
-
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
6/16/2021
Altimmune, Inc. today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801.
-
Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference
5/27/2021
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare Conference, being held June 1 - 4, 2021.
-
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
-
Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™
5/26/2021
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced new results from a preclinical study demonstrating the ability of its AdCOVID vaccine candidate to neutralize the rapidly emerging SARS-CoV-2 B.1.351 variant of concern that originated in South Africa.
-
Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update
5/17/2021
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three months ending March 31, 2021 and provided a corporate update.
-
Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
5/11/2021
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021.